APEX1 and nonpapillary renal cell carcinoma: Although APEX1 has been reported diagnosis value of ccRCC, its clinical practical prospective was still a long way.40 In recent years, the potential of snoRNA as biomarkers has been graduated recognized.15, 16, 41 For example, SNORA42 was identified as a novel diagnostic, predictive biomarker and prospective therapeutic targets for CRC patients.15 In our study, we identified a six‐snoRNA signature as the diagnosis marker depending on TCGA database and validated its value to distinguish ccRCC patients and healthy people in tissue and serum samples.